Physician profile
Timothy N Young
NPI 1962403071
$3,995.65
in general payments reported to CMS, 2019-2025
23 companies · $920 in 2025
The $920 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $203 · 2021: $677 · 2022: $485 · 2023: $711 · 2024: $846 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,026.58 | 2019-2025 | Argos, Ngenuity, Clareon |
| Ocular Therapeutix, INC. | $576.74 | 2023-2025 | Dextenza |
| Glaukos Corporation | $384.70 | 2020-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $224.56 | 2022-2025 | Durysta |
| Tarsus Pharmaceuticals, INC. | $191.67 | 2024-2025 | Xdemvy |
| Rxsight INC | $183.83 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Johnson & Johnson Surgical Vision, INC. | $177.37 | 2019-2023 | |
| Sight Sciences, INC. | $169.89 | 2021-2023 | Omni Surgical System |
| Ivantis, INC | $167.82 | 2019-2021 | |
| Oyster Point Pharma, INC. | $144.00 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Regeneron Healthcare Solutions, INC. | $95.84 | 2024-2025 | Eylea Hd, Eylea |
| New World Medical,INC. | $94.83 | 2022 | |
| Bausch & Lomb Americas INC. | $91.36 | 2023-2025 | Vyzulta, Prolensa, Miebo |
| Horizon Therapeutics Plc | $84.53 | 2022-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $77.81 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $76.25 | 2024-2025 | Oxervate |
| Allergan, INC. | $72.51 | 2019-2022 | |
| Harrow Eye, LLC | $55.25 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.50 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.34 | 2021 | |
| Genentech USA, INC. | $20.11 | 2025 | Vabysmo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyepoint US, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.